$5.06

(%)
Live
Previous Close

$5.06

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$ USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

None

KADIMASTEM LTD NEW...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

NLS Pharmaceutics is launching a preclinical program to evaluate Mazindol ER as a potential treatment for fentanyl dependence, a major global health crisis. Mazindol ER targets multiple neurotransmitter systems implicated in opioid addiction, offering a non-opioid alternative.

Related tickers: NLSP, NLSPW, KMSTF.

Read Full Article

Kadimastem has called for a special general meeting of shareholders to approve the merger with NLS Pharmaceutics. The merger aims to create a combined Nasdaq-traded biotechnology company with a robust pipeline of advanced therapies.

Related tickers: NLSP, NLSPW, KMSTF.

Read Full Article
Trending Tickers

Please sign in to view